Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D29XIA
|
|||
| Drug Name |
177-Lu-edotreotide
|
|||
| Drug Type |
Somatostatin analogue
|
|||
| Indication | Neuroendocrine cancer [ICD-11: 2B72.1; ICD-9: 209] | Phase 3 | [1] | |
| Company |
ITM Solucin Munich, Germany
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04919226) A Prospective, Randomised, Controlled, Open-label, Multicentre Study to Evaluate Efficacy, Safety and Patient-Reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-Edotreotide Compared to Best Standard of Care in Patients With Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-Positive (SSTR+), Neuroendocrine Tumours of GastroEnteric or Pancreatic Origin. U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.